NASDAQ:PCLA PicoCELA (PCLA) Stock Price, News & Analysis $0.44 +0.02 (+3.64%) As of 10/15/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About PicoCELA Stock (NASDAQ:PCLA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PicoCELA alerts:Sign Up Key Stats Today's Range$0.41▼$0.4550-Day Range$0.41▼$0.5452-Week Range$0.37▼$9.80Volume379,583 shsAverage Volume126,045 shsMarket Capitalization$11.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview PicoCELA, Inc. is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers. The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens. Preclinical studies have demonstrated robust neutralizing antibody titers and T-cell activation in animal models, supporting progression toward clinical trials. Beyond infectious disease, PicoCELA is exploring oncology applications in which tumor-associated antigens are presented on its nanoscaffold to stimulate a targeted immune attack against cancer cells. Founded in 2019 and headquartered in Connecticut, PicoCELA went public via a Nasdaq listing in 2021. The company collaborates with academic research centers and contract development organizations across the United States to advance its preclinical and future clinical-stage programs. PicoCELA’s leadership team comprises experienced executives and scientific founders with backgrounds in immunology, protein engineering and vaccine development, positioning the company to address unmet medical needs through its modular nanoparticle technology.AI Generated. May Contain Errors. Read More Receive PCLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PicoCELA and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PCLA Stock News HeadlinesPicoCELA Inc. Reports Interim Financial Results for March 2025September 26, 2025 | tipranks.comPicoCELA Inc. Issues Restricted Common Shares to MCC and You PlanningAugust 30, 2025 | tmcnet.comThe 7 Warning Signals Flashing Red Right NowA free report revealing the 7 key indicators that have predicted every major economic collapse since 1929. Right now, all seven are flashing red simultaneously for the first time since 2007. These aren't the signals you'll see on CNBC. | American Alternative (Ad)PicoCELA Strengthens Financial Position with New Share IssuanceAugust 29, 2025 | tipranks.comPicoCELA Inc. Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyAugust 29, 2025 | prnewswire.comPicoCELA Inc. Issues Restricted Common Shares to Nikken Lease Kogyo Co. Ltd.May 1, 2025 | prnewswire.comPicoCELA Inc. Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyApril 24, 2025 | prnewswire.comPicoCELA Inc. American Depositary Shares (PCLA) Institutional HoldingsMarch 30, 2025 | nasdaq.comSee More Headlines PCLA Stock Analysis - Frequently Asked Questions How have PCLA shares performed this year? PicoCELA's stock was trading at $4.55 at the start of the year. Since then, PCLA shares have decreased by 90.4% and is now trading at $0.4352. When did PicoCELA IPO? PicoCELA (PCLA) raised $10 million in an IPO on Wednesday, January 15th 2025. The company issued 2,000,000 shares at a price of $4.00-$6.00 per share. Benjamin Securities and Prime Number Capital served as the underwriters for the IPO. How do I buy shares of PicoCELA? Shares of PCLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/15/2025Fiscal Year End9/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Electric Lighting & Wiring Equipment Sub-IndustryElectrical Equipment Current SymbolNASDAQ:PCLA CIK2018462 WebN/A Phone81 03-6661-2780FaxN/AEmployees53Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.03 Current Ratio2.19 Quick Ratio1.74 Sales & Book Value Annual Sales$758.50 million Price / Sales0.02 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares27,216,000Free FloatN/AMarket Cap$11.70 million OptionableN/A BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:PCLA) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PicoCELA Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PicoCELA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.